In a report released on January 30, Rasmus Engberg from Kepler Capital maintained a Buy rating on Evolution Gaming Group AB (EVO – Research ...

Goldman Sachs downgrades MGY and OXY, reinstates coverage on EXE. MGY's outperformance reflected in current stock price, ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The combined value of all investment products tracking the NDX® ecosystem globally exceeds $500 billion94 Exchange Traded Products track NDX® in ...